D’Haens, G.R., Panaccione, R., Higgins, P.D., Vermeire, S., Gassull, M., Chowers, Y., Hanauer, S.B., Herfarth, H., Hommes, D.W., Kamm, M., Löfberg, R., Quary, A., Sands, B., Sood, A., Watermeyer, G., Lashner, B., Lémann, M., Plevy, S., Reinisch, W., Schreiber, S., Siegel, C., Targan, S., Watanabe, M., Feagan, B., Sandborn, W.J., Colombel, J.F. and Travis, S. (2011) The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? The American Journal of Gastroenterology, 106, 199-212.
http://dx.doi.org/10.1038/ajg.2010.392

has been cited by the following article:

• TITLE: Biological Therapy in IBD—Is There Any Optimal End Point?

  AUTHORS: Klaudia Farkas, Tamás Molnár

  KEYWORDS: Crohn’s Disease, Ulcerative Colitis, Biological Therapy, Discontinuation

  JOURNAL NAME: Health, Vol.6 No.11, May 28, 2014

  ABSTRACT: Biological therapy has been used in the treatment of inflammatory bowel disease (IBD-Crohn’s disease [CD], ulcerative colitis [UC]) for more than a decade. Although guidelines exist on how to start and adjust biological therapy, information on when and how it should be stopped is still scarce. In this review, our aim is to summarize the results of the recently published papers on the outcome of the discontinuation of biological therapy in patients with CD and UC.